LVW Advisors LLC Purchases New Shares in Axon Enterprise, Inc $AXON

LVW Advisors LLC purchased a new stake in Axon Enterprise, Inc (NASDAQ:AXON) during the 2nd quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The fund purchased 329 shares of the biotechnology company’s stock, valued at approximately $272,000.

Several other large investors have also added to or reduced their stakes in the stock. Vanguard Group Inc. boosted its holdings in Axon Enterprise by 2.2% in the first quarter. Vanguard Group Inc. now owns 8,632,008 shares of the biotechnology company’s stock valued at $4,540,005,000 after acquiring an additional 185,571 shares in the last quarter. Alliancebernstein L.P. boosted its holdings in Axon Enterprise by 15.9% in the first quarter. Alliancebernstein L.P. now owns 1,284,935 shares of the biotechnology company’s stock valued at $675,812,000 after acquiring an additional 175,890 shares in the last quarter. Westfield Capital Management Co. LP raised its holdings in Axon Enterprise by 29.8% in the first quarter. Westfield Capital Management Co. LP now owns 927,801 shares of the biotechnology company’s stock worth $487,977,000 after purchasing an additional 212,931 shares in the last quarter. Northern Trust Corp raised its holdings in Axon Enterprise by 1.2% in the first quarter. Northern Trust Corp now owns 725,720 shares of the biotechnology company’s stock worth $381,692,000 after purchasing an additional 8,794 shares in the last quarter. Finally, Jennison Associates LLC raised its holdings in Axon Enterprise by 23,203.7% in the first quarter. Jennison Associates LLC now owns 614,053 shares of the biotechnology company’s stock worth $322,961,000 after purchasing an additional 611,418 shares in the last quarter. Institutional investors own 79.08% of the company’s stock.

Axon Enterprise Trading Down 0.5%

NASDAQ AXON opened at $708.84 on Monday. Axon Enterprise, Inc has a 12 month low of $388.37 and a 12 month high of $885.91. The stock has a market cap of $55.64 billion, a P/E ratio of 175.02, a P/E/G ratio of 27.53 and a beta of 1.40. The stock’s fifty day moving average price is $758.60 and its 200-day moving average price is $703.76. The company has a current ratio of 2.95, a quick ratio of 2.71 and a debt-to-equity ratio of 0.63.

Axon Enterprise (NASDAQ:AXON) last released its earnings results on Monday, August 4th. The biotechnology company reported $2.12 EPS for the quarter, topping analysts’ consensus estimates of $1.54 by $0.58. Axon Enterprise had a return on equity of 6.80% and a net margin of 13.64%.The firm had revenue of $668.54 million for the quarter, compared to analysts’ expectations of $641.77 million. During the same period in the prior year, the firm posted $1.20 earnings per share. The company’s quarterly revenue was up 32.6% on a year-over-year basis. Axon Enterprise has set its FY 2025 guidance at EPS. As a group, equities analysts forecast that Axon Enterprise, Inc will post 5.8 EPS for the current fiscal year.

Insider Activity at Axon Enterprise

In related news, CAO Jennifer H. Mak sold 77 shares of the stock in a transaction on Monday, September 15th. The stock was sold at an average price of $760.00, for a total transaction of $58,520.00. Following the sale, the chief accounting officer directly owned 15,003 shares of the company’s stock, valued at $11,402,280. This trade represents a 0.51% decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which is available at the SEC website. Also, CEO Patrick W. Smith sold 10,000 shares of the stock in a transaction on Monday, September 8th. The shares were sold at an average price of $743.64, for a total value of $7,436,400.00. Following the sale, the chief executive officer directly owned 3,043,982 shares in the company, valued at $2,263,626,774.48. This trade represents a 0.33% decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders sold a total of 44,932 shares of company stock valued at $34,408,816 over the last three months. 5.70% of the stock is owned by insiders.

Wall Street Analyst Weigh In

A number of research firms have issued reports on AXON. Morgan Stanley set a $885.00 price objective on Axon Enterprise and gave the stock an “overweight” rating in a report on Friday, July 11th. Bank of America increased their price objective on Axon Enterprise from $895.00 to $1,000.00 and gave the stock a “buy” rating in a report on Wednesday, August 6th. JPMorgan Chase & Co. increased their price objective on Axon Enterprise from $730.00 to $850.00 and gave the stock an “overweight” rating in a report on Thursday, July 17th. UBS Group reiterated a “neutral” rating and issued a $840.00 price objective (up previously from $820.00) on shares of Axon Enterprise in a report on Tuesday, August 5th. Finally, Piper Sandler began coverage on Axon Enterprise in a report on Tuesday, September 23rd. They issued an “overweight” rating and a $893.00 price objective for the company. Fourteen equities research analysts have rated the stock with a Buy rating and three have assigned a Hold rating to the company. According to MarketBeat.com, the company currently has a consensus rating of “Moderate Buy” and a consensus target price of $841.64.

Axon Enterprise Company Profile

Axon Enterprise, Inc develops, manufactures, and sells conducted energy devices (CEDs) under the TASER brand in the United States and internationally. It operates through two segments, Software and Sensors, and TASER. The company also offers hardware and cloud-based software solutions that enable law enforcement to capture, securely store, manage, share, and analyze video and other digital evidence.